secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001104659-23-127766
Event type: litigation
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Federal Circuit cancels key Tyvaso patent; Liquidia may launch Yutrepia sooner
------------------------------------------------------------------------------

- Court affirmed IPR decision canceling claims of U.S. Patent No. 10,716,793 covering Tyvaso and Tyvaso DPI.
- Liquidia can seek final FDA approval for Yutrepia unless the decision is reversed on further appeal.
- United Therapeutics can request rehearing or petition the Supreme Court; patent claims remain valid until appeals exhausted.
- Separate lawsuit filed Sep 2023 alleges Yutrepia amendments infringe new patent (11,826,327) expiring Jan 2042.
- FDA tentatively approved Yutrepia for PAH in Nov 2021; final approval also requires lifting of District Court order.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465923127766/0001104659-23-127766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465923127766/tm2333408d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-127766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer